KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Gains from Investment Securities (2020 - 2025)

Historic Gains from Investment Securities for Ginkgo Bioworks Holdings (DNA) over the last 6 years, with Q1 2025 value amounting to $207000.0.

  • Ginkgo Bioworks Holdings' Gains from Investment Securities rose 12202.13% to $207000.0 in Q1 2025 from the same period last year, while for Sep 2025 it was $207000.0, marking a year-over-year increase of 10264.84%. This contributed to the annual value of -$5.7 million for FY2024, which is 1031.35% down from last year.
  • As of Q1 2025, Ginkgo Bioworks Holdings' Gains from Investment Securities stood at $207000.0, which was up 12202.13% from -$1.5 million recorded in Q3 2024.
  • Ginkgo Bioworks Holdings' 5-year Gains from Investment Securities high stood at $29.2 million for Q3 2021, and its period low was -$107.5 million during Q4 2021.
  • Moreover, its 5-year median value for Gains from Investment Securities was $207000.0 (2025), whereas its average is -$2.4 million.
  • In the last 5 years, Ginkgo Bioworks Holdings' Gains from Investment Securities crashed by 99709.18% in 2021 and then soared by 12202.13% in 2025.
  • Over the past 5 years, Ginkgo Bioworks Holdings' Gains from Investment Securities (Quarter) stood at -$107.5 million in 2021, then soared by 73.15% to -$28.9 million in 2022, then surged by 92.67% to -$2.1 million in 2023, then grew by 27.75% to -$1.5 million in 2024, then surged by 113.55% to $207000.0 in 2025.
  • Its Gains from Investment Securities stands at $207000.0 for Q1 2025, versus -$1.5 million for Q3 2024 and -$3.2 million for Q2 2024.